Welch & Forbes LLC grew its position in Eli Lilly and Company (NYSE:LLY – Free Report) by 2.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 133,093 shares of the company’s stock after buying an additional 3,340 shares during the period. Eli Lilly and Company accounts for approximately 1.2% of Welch & Forbes LLC’s investment portfolio, making the stock its 25th largest position. Welch & Forbes LLC’s holdings in Eli Lilly and Company were worth $77,583,000 at the end of the most recent quarter.
A number of other hedge funds have also recently made changes to their positions in LLY. International Assets Investment Management LLC raised its holdings in shares of Eli Lilly and Company by 61,268.8% in the 4th quarter. International Assets Investment Management LLC now owns 7,342,780 shares of the company’s stock valued at $42,802,530,000 after purchasing an additional 7,330,815 shares in the last quarter. Sapient Capital LLC acquired a new stake in shares of Eli Lilly and Company in the 4th quarter valued at $682,139,000. J.P. Morgan Private Wealth Advisors LLC acquired a new stake in shares of Eli Lilly and Company in the 3rd quarter valued at $435,736,000. Vanguard Group Inc. raised its holdings in shares of Eli Lilly and Company by 0.9% in the 3rd quarter. Vanguard Group Inc. now owns 70,575,602 shares of the company’s stock valued at $37,908,273,000 after purchasing an additional 659,838 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA raised its stake in Eli Lilly and Company by 24.2% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,310,859 shares of the company’s stock worth $1,778,362,000 after acquiring an additional 645,473 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.
Eli Lilly and Company Trading Up 4.3 %
Shares of LLY traded up $31.77 on Monday, hitting $766.74. 3,396,224 shares of the stock traded hands, compared to its average volume of 3,090,840. The company has a quick ratio of 1.03, a current ratio of 1.35 and a debt-to-equity ratio of 1.90. The firm has a market capitalization of $728.72 billion, a P/E ratio of 112.92, a P/E/G ratio of 1.45 and a beta of 0.37. The stock’s 50 day moving average is $760.96 and its two-hundred day moving average is $673.52. Eli Lilly and Company has a 1 year low of $419.80 and a 1 year high of $800.78.
Eli Lilly and Company Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Monday, June 10th. Shareholders of record on Thursday, May 16th will be paid a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 0.68%. Eli Lilly and Company’s dividend payout ratio is currently 76.58%.
Wall Street Analyst Weigh In
Several equities research analysts recently commented on LLY shares. Barclays lifted their price target on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 7th. Wells Fargo & Company lifted their price target on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 6th. Cantor Fitzgerald reiterated an “overweight” rating and set a $885.00 price target (up from $815.00) on shares of Eli Lilly and Company in a research note on Tuesday, April 30th. TheStreet raised shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a research report on Friday, March 8th. Finally, Truist Financial raised their price objective on shares of Eli Lilly and Company from $850.00 to $892.00 and gave the stock a “buy” rating in a research report on Wednesday, May 1st. Three investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. Based on data from MarketBeat, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus price target of $757.95.
Check Out Our Latest Report on LLY
Eli Lilly and Company Company Profile
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Featured Articles
- Five stocks we like better than Eli Lilly and Company
- Profitably Trade Stocks at 52-Week Highs
- 3 CEO-Led Turnaround Stocks You Can Still Buy
- How to Use the MarketBeat Excel Dividend Calculator
- 3 Value Stocks You Can Buy Before They Become Big
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Chinese Stocks Stage Impressive Rebound
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.